Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/β-thalassemia patient

Blood

Volumn 103, Issue 7, 2004, Pages 2844-2846

  Atichartakarn, Vichai ^a   Chuncharunee, Suporn ^a   Chandanamattha, Pakorn ^a   Likittanasombat, Khanchit ^a   Aryurachai, Katcharin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEFEROXAMINE MESYLATE; HEMOGLOBIN E; THROMBIN ANTITHROMBIN COMPLEX; WARFARIN;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD LEVEL; CASE REPORT; ERYTHROCYTE TRANSFUSION; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERCOAGULABILITY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; PATIENT MONITORING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SPLENECTOMY; THROMBOSIS;

EID: 1642327238     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3094     Document Type: Article

References (17)

1. Rich S. Pulmonary hypertension. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders; 2001:1908-1935.
2. Gibbs JSR, Higenbottam TW. Recommendations on the management of pulmonary hypertension in clinical practice. Heart. 2001;86(suppl 1):i1-i13.
3. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac Involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411-3416.
4. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with β-thalassemic disorders. Int J Hematol. 2003;78:139-145.
5. Adedeji MO, Cespedes J, Allen K, et al. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med. 2001;125:1436-1441.
6. Fucharoen S, Yongchaiyud P, Wasi P. Hypoxaemia and the effect of aspirin in thalassaemia. Southeast Asian J Trop Med Public Health. 1981;12:90-93.
7. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99:36-43.
8. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/β-thalassaemic patients. Br J Haematol. 2002;118:893-898.
9. Eldor A, Lellouche F, Goldfarb A, et al. In vivo platelet activation in beta thalassemia major reflected by increased platelet thromboxane urinary metabolites. Blood. 1991;77:1749-1753.
10. Del-Principe D, Menichelli A, Di Giullo S, et al. PADGEM/GMP-140 expression on platelet membrane from homozygous β-thalassaemia patients. Br J Haematol. 1993;84:111-117.
11. Ruf A, Pick M, Deutsch V, et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β-thalassaemia major. Br J Haematol. 1997;98:51-56.
12. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. In vivo platelet activation and hyperaggregation in hemoglobin E/β-thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77:299-303.
13. Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol. 1999;107:300-302.
14. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. Circulation. 1989;80:1198-1206.
15. Pasin M, Yavuzer S, Tekin M, et al. Oxygen free radical dependent increased platelet function in β-thalassemia major patients. Thromb Res. 1998;92:283-286.
16. Claster S, Hammer M, Hagar W, et al. Treatment of pulmonary hypertension in sickle cell disease with transfusion [abstract]. Blood. 1999;94:420a.
17. Wandersee NJ, Lee JC, Deveau SA, et al. Reduced incidence of thrombosis in mice with hereditary spherocytosis following neonatal treatment with normal hematopoietic cells. Blood. 2001;97:3972-3975.